<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02192632</url>
  </required_header>
  <id_info>
    <org_study_id>ADP-BPO</org_study_id>
    <secondary_id>1402-051-555</secondary_id>
    <nct_id>NCT02192632</nct_id>
  </id_info>
  <brief_title>Dermatologists' Educational Demonstration for Epiduo Application</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and tolerability of this combination
      gel compared with BPO monotherapy in Korean patients, and test clinical practicability of
      dermatologists' educational demonstration for how to apply this gel in reducing uncomfortable
      irritations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentile reduction of non-inflammatory &amp; inflammatory acne lesions</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurement of decreases in both non-inflammatory &amp; inflammatory acne lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of local irriation effect counts (erythema, scaling, dryness, itching)</measure>
    <time_frame>12 week</time_frame>
    <description>Calcuation of total number of local irriation effect counts (erythema, scaling, dryness, itching)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Facial Acne</condition>
  <condition>Local Adverse Effects</condition>
  <arm_group>
    <arm_group_label>Epiduo- dermatologist's detailed instruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomly assigned to side of epiduo application, half of total patients were also re-assigned into detailed instruction for application of epiduo from dermatologist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epiduo- drug insert only gruop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomly assigned to side of epiduo application, half of total patients were also re-assigned into drug insert only group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPO group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After randomly assigned to side of BPO application, patients apply BPO during 12 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epiduo once daily with detailed instruction for how to apply it</intervention_name>
    <arm_group_label>Epiduo- dermatologist's detailed instruction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epiduo- once daily, simple instruction for application</intervention_name>
    <arm_group_label>Epiduo- drug insert only gruop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPO once daily</intervention_name>
    <arm_group_label>BPO group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild to moderate acne were evaluated by Leeds revised acne grade from 2 to 6

          -  age: 18-40

        Exclusion Criteria:

          -  pregnancy

          -  mental illness

          -  intake of oral isotretinoin within 6 months

          -  application of the other oral or topical acne medications

          -  chemical peeling or light based treatments within 6 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dermatology, Seoul National University</name>
      <address>
        <city>Seoul</city>
        <state>Joungro</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2014</study_first_submitted>
  <study_first_submitted_qc>July 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2014</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Dae Hun Suh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene, Benzoyl Peroxide Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

